WindRose Health Investors Completes Recapitalization of Verified Clinical Trials in Healthcare Industry

WindRose Health Investors Announces Recapitalization of Verified Clinical Trials

On August 6, 2026, WindRose Health Investors, a private equity firm based in New York, revealed its successful recapitalization of Verified Clinical Trials LLC (VCT), a global leader in patient safety, compliance, and data integrity in clinical research. This strategic move is expected to bolster VCT’s innovative solutions as the healthcare sector witnesses rapid advancements.

With Howard Miller taking the reins as the new Chief Executive Officer, the founders of VCT, Dr. Mitchell Efros and Kerri Weingard, ANP, will remain actively engaged in guiding the company's future direction. This ensures that VCT benefits from the founders' invaluable expertise while integrating WindRose's extensive healthcare investment experience.

Dr. Efros commented on the partnership, stating, "This collaboration with WindRose marks an exhilarating time for VCT. Over the past 16 years, our team has worked diligently to cultivate proprietary data assets and processes essential to safeguarding patient well-being and maintaining data integrity in clinical research." He also highlighted that WindRose's extensive healthcare knowledge and Miller’s impressive history in scaling high-growth enterprises positions them as ideal partners.

With WindRose's investment, VCT plans to capitalize on the escalating demand for its premier solutions. In addition, it aims to enhance its data and analytics capabilities, which will provide better services for pharmaceutical sponsors, Contract Research Organizations (CROs), and clinical trial sites. This partnership is set to elevate VCT’s subject verification solutions, making them the gold standard in clinical trial compliance, thus expediting the path for effective therapies to reach patients.

CJ Burnes, a partner at WindRose, referred to VCT's unique offering as a game-changer. He noted, "VCT's solution actively mitigates downstream risks for all involved in clinical research, promoting participant safety, enhancing data quality, and lessening avoidable disruptions in trials. We are thrilled to collaborate with Howard, Mitchell, and Kerri, accelerating VCT's growth through further investments in its platform and capabilities."

This recapitalization is not just a financial maneuver but a commitment to innovation in healthcare, promising the future enhancement of clinical trials. It assures that VCT remains at the forefront in improving how clinical trials are conducted and ensuring safety and compliance while maintaining integrity in clinical data.

Cantor Fitzgerald & Co. played a crucial role as the exclusive financial advisor for VCT, while McDermott Will & Schulte LLP served as their legal advisor. For WindRose, legal counsel was provided by Latham & Watkins LLP.

WindRose Health Investors specializes in making equity investments in the healthcare sector, focusing on companies displaying profitable business frameworks and effective solutions. With around $8 billion in assets under management, WindRose invests in various companies across the United States, positioning them as a pivotal player in healthcare investments. As part of their ongoing commitment to the industry, more information about WindRose can be obtained through their official communications.

In the competitive landscape of clinical trials, Verified Clinical Trials stands out as a critical provider. Their dedicated solutions are crafted to tackle key challenges, including preventing duplicate enrollments and mitigating protocol violations within clinical research. Utilizing their advanced, secure global database, VCT works closely with researchers, sponsors, and CROs to enhance subject safety and ensure adherence to protocol compliance, thereby protecting the integrity of the critical data upon which health outcomes depend.

For additional insights about Verified Clinical Trials, interested parties can explore their offerings at verifiedclinicaltrials.com, ensuring they remain informed about evolving capabilities in clinical research safety and compliance.